stockportfolio.pro
Immunome, Inc. (IMNM)
Healthcare · Biotechnology · NasdaqCM
Immunome, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $14.02M | $9.04M | $6.94M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-10.44M | $-17.84M | $-24.71M | $-36.90M | $-106.81M | $-292.96M | $-212.39M |
| Net margin | — | — | — | — | -761.9% | -3240.4% | -3060.0% |
Source: Immunome, Inc. SEC filings (10-K).
Explore 7 years of Immunome, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IMNM in your portfolio →
Immunome, Inc. financial history by metric
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. — frequently asked questions
What is Immunome, Inc.'s revenue?
Immunome, Inc. (IMNM) reported revenue of $6.94M for fiscal year 2025, down 23.2% from the prior year, according to its SEC filings.
Is Immunome, Inc. profitable?
No — IMNM reported a net loss of $-212.39M in fiscal 2025.
What is IMNM's P/E ratio?
Immunome, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Immunome, Inc. have?
As of fiscal year 2025, IMNM carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Immunome, Inc.'s market cap?
Immunome, Inc. (IMNM) has a market capitalization of about $2.07B, based on the latest data in our nightly-refreshed cache.
When does Immunome, Inc.'s fiscal year end?
IMNM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Immunome, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.